Welcome to our dedicated page for PACS Group SEC filings (Ticker: PACS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS Group, Inc. reported that director Taylor S. Leavitt received a grant of 4,287 restricted stock units (RSUs), with no cash paid per share. Each RSU will convert into one share of common stock when it vests.
According to the terms, 100% of the RSUs vest on the earlier of July 1, 2027 or the date of the next annual meeting following the grant, as long as Leavitt continues serving the company. After this award, Leavitt holds 19,784 shares of common stock directly.
Dilsaver Evelyn S reported acquisition or exercise transactions in this Form 4 filing.
PACS Group, Inc. director Evelyn S. Dilsaver received an equity award in the form of 4,287 shares of Common Stock as a grant, reported at a price of $0.00 per share, indicating compensation rather than a market purchase. This award is structured as restricted stock units (RSUs), each convertible into one share of Common Stock upon vesting. All of the RSUs will vest on the earlier of July 1, 2027 or the date of the next annual meeting following the grant, assuming she continues to serve the company. After this grant, her directly held position reported in this filing is 36,085 shares of Common Stock.
Mark Hancock reported multiple sales of Common stock of PACS under a Form 144 filing. The filing lists several dispositions between 06/15/2026 and 07/02/2026, including transactions of 153,254 shares on 06/15/2026 and 138,069 shares on 06/25/2026.
The sales list per‑trade proceeds in dollars alongside share counts and identify Citigroup Global Markets Inc at 388 Greenwich Street as the broker. The filing also shows an earlier block of 54,626,199 shares described as "shares acquired at formation of the issuer" dated 03/01/2023.
Mark Hancock reported multiple proposed sales of common stock under a Form 144. The filing lists discrete transactions on 06/15/2026, 06/16/2026, 06/17/2026, 06/25/2026, 06/26/2026, and 07/01/2026 with individual share counts and sale proceeds shown. The transactions are reported as sales of issuer common stock.
PACS affiliate Mark Hancock reported sales totaling 500,000 shares of Common Stock in multiple transactions during June 2026. The filing lists five dispositions dated 06/15/2026 through 06/26/2026 with aggregate proceeds of $18,875,341.54.
The record shows these shares were part of the holdings tied to formation (listed as 54,626,199 shares acquired at formation) but that figure is presented as an issuer/balance item. The schedule is a regulatory notice of proposed or recent sales by an affiliate; the filing does not state any intended use of proceeds or whether transactions were pursuant to a trading plan.
PACS Group, Inc. director and executive vice chair Mark Hancock reported open-market sales of a total of 200,000 shares of common stock. The trades occurred on June 25 and 26, 2026 at weighted average prices around $40–$41 per share.
The filing shows Hancock continues to hold more than 54 million shares of PACS Group common stock directly after these transactions. According to a footnote, the June 2026 sales were effected under a pre‑arranged Rule 10b5-1 trading plan adopted on March 11, 2026, indicating they were scheduled in advance rather than timed discretionarily.
PACS Group, Inc. Chief Accounting Officer Michelle Renee Lewis sold 15,000 shares of common stock in an open-market transaction at a weighted average price of about $40.0119 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and she continues to hold 370,338 shares directly.
Mark Hancock sold Common stock reported on a Form 144. The filing lists multiple open-market dispositions: 153,254 shares on 06/15/2026 for $5,568,759.95, 63,680 shares on 06/17/2026 for $2,248,413.44, 83,066 shares on 06/16/2026 for $2,982,385.05, and 138,069 shares on 06/25/2026 for $5,567,701.46.
The record also shows 54,626,199 shares were "acquired at formation of the issuer" on 03/01/2023. The transactions are presented as sales with gross proceeds shown next to each trade date.
PACS reported insider sales by Mark Hancock via a Form 144 filing: 153,254 shares sold on 06/15/2026, 83,066 shares sold on 06/16/2026, and 63,680 shares sold on 06/17/2026. The transactions are listed as Common stock dispositions with cash consideration.
PACS submitted a Form 144 notice listing proposed sales of Common Stock through J.P. Morgan Securities LLC. The filing lists a proposed sale quantity of 45,000 shares, a beneficially held figure of 1,748,250 shares, and a total share count of 158,272,376 with an effective date of 06/25/2026. The notice also identifies RSU vesting-related shares of 31,616 (04/15/2026) and 13,384 (04/15/2025) shown as compensation.